Challenges and Strategies for the Recruitment of Patients With Schizophrenia in a Research Setting
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Challenges and Strategies for the Recruitment of Patients With Schizophrenia in a Research Setting
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-08-30
DOI
10.1093/ijnp/pyac058
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to disease
- (2022) Daniel C. Javitt et al. SCHIZOPHRENIA RESEARCH
- Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials
- (2022) Heidi Taipale et al. JAMA Psychiatry
- Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
- (2022) Michael Davidson et al. SCHIZOPHRENIA BULLETIN
- Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: A meta-analysis of randomised, placebo-controlled trials
- (2021) Kah Kheng Goh et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
- (2021) Stephen K. Brannan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Deficits in Pre-attentive Processing of Spatial Location and Negative Symptoms in Subjects at Clinical High Risk for Schizophrenia
- (2021) Pejman Sehatpour et al. Frontiers in Psychiatry
- Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
- (2021) Felipe V. Gomes et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- How do we address treating the negative symptoms of schizophrenia pharmacologically?
- (2021) Joshua T. Kantrowitz EXPERT OPINION ON PHARMACOTHERAPY
- Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia
- (2021) Anissa Abi-Dargham et al. SCHIZOPHRENIA BULLETIN
- Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions
- (2021) Joshua T. Kantrowitz CNS DRUGS
- Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058
- (2021) Pejman Sehatpour et al. NEUROPSYCHOPHARMACOLOGY
- Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients
- (2020) Joshua T. Kantrowitz et al. NEUROPSYCHOPHARMACOLOGY
- Adjunctive sapropterin dihydrochloride treatment in schizophrenia: A positive proof-of-concept, rater-blind, randomized, multivitamin-controlled study
- (2020) Catherine L. Clelland et al. SCHIZOPHRENIA RESEARCH
- Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers
- (2020) Joshua T. Kantrowitz et al. NEUROPSYCHOPHARMACOLOGY
- A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
- (2020) Kenneth S. Koblan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches
- (2020) Joshua T. Kantrowitz CNS DRUGS
- The Role of Social Media in Enhancing Clinical Trial Recruitment: Scoping Review
- (2020) Ida Darmawan et al. JOURNAL OF MEDICAL INTERNET RESEARCH
- Significant improvement in treatment resistant auditory verbal hallucinations after 5 days of double-blind, randomized, sham controlled, fronto-temporal, transcranial direct current stimulation (tDCS): A replication/extension study
- (2019) Joshua T. Kantrowitz et al. Brain Stimulation
- Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study
- (2019) Ragy R. Girgis et al. PSYCHIATRY RESEARCH
- Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis
- (2019) Stefan Leucht et al. NEUROPSYCHOPHARMACOLOGY
- Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders
- (2018) Daniel C. Javitt et al. JAMA Psychiatry
- Recruiting for a pragmatic trial using the electronic health record and patient portal: successes and lessons learned
- (2018) Emily Pfaff et al. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
- The Representativeness of Participants With Severe Mental Illness in a Psychosocial Clinical Trial
- (2018) John Lally et al. Frontiers in Psychiatry
- A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia
- (2017) Ragy R Girgis et al. NEUROPSYCHOPHARMACOLOGY
- OnTrackNY: The Development of a Coordinated Specialty Care Program for Individuals Experiencing Early Psychosis
- (2017) Iruma Bello et al. PSYCHIATRIC SERVICES
- A tale of two sites: Differential impairment of frequency and duration mismatch negativity across a primarily inpatient versus a primarily outpatient site in schizophrenia
- (2017) Migyung Lee et al. SCHIZOPHRENIA RESEARCH
- A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing–Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder
- (2016) Joshua T. Kantrowitz et al. JOURNAL OF CLINICAL PSYCHIATRY
- A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia
- (2016) Ragy R Girgis et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Social cognition in schizophrenia
- (2015) Michael F. Green et al. NATURE REVIEWS NEUROSCIENCE
- The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis
- (2015) Paolo Fusar-Poli et al. SCHIZOPHRENIA BULLETIN
- A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy
- (2015) L. Fredrik Jarskog et al. SCHIZOPHRENIA RESEARCH
- A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results
- (2015) Tessa Kennedy-Martin et al. Trials
- Barriers and facilitators to recruitment in mental health services: Care coordinators' expectations and experience of referring to a psychosis research trial
- (2014) Sandra Bucci et al. PSYCHOLOGY AND PSYCHOTHERAPY-THEORY RESEARCH AND PRACTICE
- Placebo Response in Antipsychotic Clinical Trials
- (2014) Bret R. Rutherford et al. JAMA Psychiatry
- Detection of people at risk of developing a first psychosis: comparison of two recruitment strategies
- (2012) J. Rietdijk et al. ACTA PSYCHIATRICA SCANDINAVICA
- From Perception to Functional Outcome in Schizophrenia
- (2012) Michael F. Green et al. ARCHIVES OF GENERAL PSYCHIATRY
- A Systematic Review and Meta-Analysis of Recovery in Schizophrenia
- (2012) E. Jaaskelainen et al. SCHIZOPHRENIA BULLETIN
- Strategies to enhance patient recruitment and retention in research involving patients with a first episode of mental illness
- (2008) Ivana Furimsky et al. Contemporary Clinical Trials
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now